Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary.
OBJECTIVE
To determine overexpression of p53, EGFR, c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results, especially, coexisting overexpression of p53 and one of the member of type I growth factor receptor family.


METHODS
Overexpressions of the p53, EGFR, c-erbB-2 and c-erbB-3 protein were studied by immunohistochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary.


RESULTS
11 (39.3%), 13 (46.4%), and 14 (50.0%) were stained positively with p53, c-erbB-2 and c-erbB-3 monoclonal antibodies. 13 (46.4%) was stained positively with EGFR polyclonal antibody. There were no relationship between p53, EGFR, C-erbB-2, c-erbB-3 and histologic grade, lymph node metastasis. The percentage of tumors with over expression of p53, EGFR, C-erbB-2 and c-erbB-3 was higher in those with stage II-III tumors compared with those with stage I, in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53, EGFR, c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR, c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive.


CONCLUSIONS
Overexpression of p53, EGFR, c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR, c-erbB-2 and c-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.
Leng
J
J
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730.
Lang
J
J
Shen
K
K
Guo
L
L
D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000235:genetics* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression; D018815:Genes, erbB; D018773:Genes, erbB-1; D018734:Genes, erbB-2; D016158:Genes, p53; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D015996:Survival Rate